First Vegan Friendly Glucosamine Supplement Launched
28 Sep 2016 --- TSI Group Co. Ltd. (TSI) has announced the launch of GlucosaGreenDF, the world’s first non-shellfish glucosamine branded product line. Produced by an innovative and patent-pending direct fermentation technology, and with regulatory approval, TSI expects the supplement to revolutionize the global glucosamine market.
Over the years, glucosamine has enjoyed significant growth as one of the most popular ingredients in the global joint care category, and it seems its success is reaching other categories too.
According to Innova Market Insights data, the use of Glucosamine in bone health supplements category is up nearly 6% from 2015 to 2016 YTD, and up 11.5% in the immune health supplements category.
However, historically, the production of glucosamine ingredients has been largely dependent on shellfish derived chitin as a starting material.
However, chitin has exhibited significant challenges, such as a frequently unclear supply chain, inconsistent quality and potentially harmful environmental impact due to manufacturing conditions.
Furthermore, shellfish derived glucosamine ingredients are not suitable for vegetarians and vegans, and their uses are also prohibited by certain religions.
The new glucosamine ingredient line from TSI is the first to offer an alternative.
According to TSI’s CEO Joe Zhou, “The patent pending, direct fermentation manufacturing technology that supports GlucosaGreenDF is considered ‘disruptive’ since it effectively addresses and offers efficient solutions to all of the challenges inherent in shellfish derived chitin production processes.”
Zhou continued, “The GlucosaGreenDF process is a totally transparent, fully traceable, cost-effective and environmentally-friendly solution for brands and ultimately the consumer.”
The GlucosaGreenDF glucosamine ingredient line includes Glucosamine Hydrochloride, Glucosamine Sulfates and N-Acetyl Glucosamine options. All grades are manufactured under the highest quality CGMP conditions and they are tested to ensure full compliance with international monographs such as USP and the European Pharmacopeia.
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.
